क्लिनिकल और प्रयोगशाला अनुसंधान के इतिहास

  • आईएसएसएन: 2386-5180
  • जर्नल एच-इंडेक्स: 17
  • जर्नल उद्धरण स्कोर: 6.26
  • जर्नल प्रभाव कारक: 5.31
में अनुक्रमित
  • जेनेमिक्स जर्नलसीक
  • चीन राष्ट्रीय ज्ञान अवसंरचना (सीएनकेआई)
  • उद्धरण कारक
  • रिसर्च जर्नल इंडेक्सिंग की निर्देशिका (डीआरजेआई)
  • पबलोन्स
  • यूरो पब
  • गूगल ज्ञानी
  • शेरपा रोमियो
  • गुप्त खोज इंजन लैब्स
इस पृष्ठ को साझा करें

अमूर्त

Serological Investigation against Recombinant Hepatitis B Virus Surface Mutants in Vaccinated Healthcare Workers and HBV Chronic Carriers with Anti-HBs

Shiva Jafari, Seyed Reza Jooya, Seyed Mehdi Boutorabi and Reza Hajhosseini

Aims: Hepatitis B virus (HBV) infection is still a worldwide public health problem despite regular vaccination programs around the world. This study was performed to investigate the serological pattern of vaccinated subjects against recombinant repeatedly isolates of hepatitis B virus surface mutants, and evaluate the characteristics of HBsAg positive patients having HBs antibodies concurrently.

Methods: Fifty vaccinated health care staffs participated in this study accompanied with five patients simultaneously carry HBsAg and anti-HBs antibody. For all the samples, the anti-HBs Enzyme-linked immunosorbent assay was performed for detecting antibody against thirteen recombinant mutants.

Findings: The results showed that all vaccinated individuals had clinically sufficient protective antibody values (greater than 10 MIU/ml) with the mean value of 165 mIU/ml ± 29 mIU/ml. whereas, only 30% of individuals showed the complete protective neutralizing immune response to all specific HBsAg recombinant mutants. The lack of responsiveness mainly observed in three of HBV mutants; D144A (70%), Q129R (48.5%) and G145R (ad) (30%) respectively. The HBV chronic carriers with anti-HBs showed having the Q129R, G145R (ay), D144A, T126 N, T126s and G145 (ad) escaped mutants.

Conclusion: The lack of responsiveness to some specific HBV mutants in vaccinated subjects, point out the potential risk of exposure to hepatitis B virus mutants.